MedPath

Prospective randomized multicenter comparison of indocyanine green (ICG)-99mTc-nanocolloid vs. 99mTc-nanocolloid plus an intraoperative injection of ICG for the detection and surgical resection of the sentinel nodes in patients with prostate cancer

Phase 2
Conditions
prostate cancer
prostate carcinoma
10038597
10036958
Registration Number
NL-OMON45195
Lead Sponsor
Antoni van Leeuwenhoek Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

• Histologically proven prostate cancer;
• Patients are clinically node negative and metastases negative (N0, M0);
• Increased risk of nodal metastases according to the Briganti nomogram (> 7%);
• Scheduled for surgical (laparoscopic or robotic) prostatectomy including nodal dissection.

Exclusion Criteria

• History of iodine allergy;
• Hyperthyroid or thyroidal adenoma;
• Kidney insufficiency.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Number of positive patients (as determined following histopathological<br /><br>analysis of the excised nodes).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Collection of the below summarized information will provide us an answer to the<br /><br>following secondary endpoints:<br /><br>1. What is the role of preoperative SPECT/CT for the identification of SNs<br /><br>draining from the prostate?<br /><br>2. Is there a difference between ICG-99mTc-nanocolloid and free ICG in the<br /><br>optical identification of SNs of the prostate?</p><br>
© Copyright 2025. All Rights Reserved by MedPath